Antibodies for Neoplastic Disease

Solid Tumors
  • Ian T. W. Matthews
Part of the Methods in Molecular Medicine book series (MIMM, volume 40)


The ease with which polyclonal, monoclonal, and engineered antibody fragments can be prepared allows access to a series of reagents with high selectivity and affinity. These reagents therefore have long held promise as a means of influencing the growth and spread of malignant disease. Over a number of decades therapeutic antibodies have been developed either as single entities or conjugated to a variety of potential disease-ameliorating agents.


Ovarian Cancer Human Epidermal Growth Factor Receptor Bispecific Antibody Metastatic Colorectal Carcinoma Idiotypic Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Liu, S. Y. and Press, O. W. (1997) The potential for immunoconjugates in lym-phoma therapy. Haematol. Oncol. Clin. North Am. 11, 987–1006.CrossRefGoogle Scholar
  2. 2.
    Frankel, A. E., Laver, J. H., Willingham, M. C., Burns, L. J., Kersey, J. H., and Vallera, D. A. (1997) Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk. Lym-phoma 26, 287–298.Google Scholar
  3. 3.
    LoRusso, P. M., Lomen, P. L., Redman, B. G., Poplin, E., Bander, J. J., and Valdivieso, M. (1995) Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am. J. Clin. Oncol. 18, 307–312.CrossRefPubMedGoogle Scholar
  4. 4.
    Laske, D. W., Muraszko, K. M., Oldfield, E. H., DeVroom, H. L., Sung, C., Dedrick, R. L. Simon, T. R., Clandrea, J., Copeland, C., Katz, D., Greenfield, L., Groves, E. S., Houston, L. L., and Youle, R. J. (1997) Intraventricular immun-otoxin therapy for leptomeningeal neoplasia. Neurosurgery 41, 1039–1049.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen, S. Y., Yang, A. G., Chen, J. D., Kute, T., King, C. R., Collier, J., Cong, Y., Yao, C., and Huang, X. F. (1997) Potent antitumour activity of a new class of tumour-specific killer cells. Nature 385, 78–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Yarranton, G. (1998) Antibody-calicheamicin conjugates for the treatment of cancer. Antibody Engineering. New Technology, Application and Commercialisation. IBC event code IB 146. March 2-3, The Royal Society, London, UK.Google Scholar
  7. 7.
    Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., Blattler, W. A., and Chari, R. V. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA 93(16), 8618–8623.CrossRefPubMedGoogle Scholar
  8. 8.
    Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. (1993) Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219–1224.CrossRefPubMedGoogle Scholar
  9. 9.
    Goldenberg, D. M., ed. (1995) Cancer Therapy with Radiolabelled Antibodies. CRC, Boca Raton, FL.Google Scholar
  10. 10.
    Blumenthal, R. D., Sharkey, R. M., Natale, A. M., Kashi, R., Wong, G., and Goldenberg, D. M. (1994) Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res. 54, 142–151.PubMedGoogle Scholar
  11. 11.
    Hird, V., Maraveyas, A., Snook, D., Dhokia, B. Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., and Epenetos, A. A. (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 68(2), 403–406.CrossRefPubMedGoogle Scholar
  12. 12.
    Canevari, S., Miotti, S., Bottere, F., Valota, O., and Colnaghi, M. I. (1993) Ovarian carcinoma therapy with monoclonal antibodies. Hybridoma 12, 501–507.CrossRefPubMedGoogle Scholar
  13. 13.
    Riva, P., Tison, V., Arista, A., et al. (1993) Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int. J. Biol. Markers 8, 192–197.PubMedGoogle Scholar
  14. 14.
    Welt, S., Divgi, C. R., Kemeny, N., et al. (1994) Phase I/II study of iodine 131-labelled monoclonal antibody A3 3 in patients with advanced colon cancer. J. Clin. Oncol. 12, 1561–1571.PubMedGoogle Scholar
  15. 15.
    Riva, P., Arista, A., Tison, V., et al. (1994) Intralesional radioimmunotherapy of malignant glioma. An effective treatment in recurrent tumours. Cancer 73, 1076–1082.CrossRefPubMedGoogle Scholar
  16. 16.
    Kalofonos, H. P., Pawlikowska, T. R., Hemingway, A., et al. (1989) Antibody guided diagnosis and therapy of brain gliomas using radiolabelled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phos-phatase. J. Nucl. Med. 30, 1636–1645.PubMedGoogle Scholar
  17. 17.
    Grana, C., Chinol, M., Magnani, P., Corti, A., Sidoli, A., Siccardi, A. G., and Paganelli, G. (1996) In vivo tumour targeting based on the avidin-biotin system. Tumour Targeting 2, 230–239.Google Scholar
  18. 18.
    Stillwagon, G. B., Order, S. E., Klein, J. L., et al. (1987) Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with I-131 anti-CEA: a Radiation Therapy Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 13, 687–695.CrossRefPubMedGoogle Scholar
  19. 19.
    Order, S. E., Stillwagon, G. B., Klein, J. L., et al. (1985) Iodine-131-antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J. Clin. Oncol. 3, 1573–1582.PubMedGoogle Scholar
  20. 20.
    Order, S. E., Vriesendorp, H. M., Klein, J. L., and Leichner, P. K. (1988) A phase I study of 90yttrium antiferritin: dose escalation and tumour dose. Antibody Immunoconj. Radiopharm. 1, 163–168.Google Scholar
  21. 21.
    Zeng, Z. C., Tang, Z. Y., Xie, H., et al. (1993) Radioimmunotherapy for unresectable hepatocellular carcinoma using 131-Hepama-1 mAb: preliminary results. J. Cancer Res. Clin. Oncol. 119, 257–259.CrossRefPubMedGoogle Scholar
  22. 22.
    Siegel, J. A., Pawlyk, D. A., Lee, R. E., et al. (1990) Tumor, red marrow and organ dosimetry for 131I-labelled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res. 50, 1039s–1042s.PubMedGoogle Scholar
  23. 23.
    Thirion, S., Motmans, K., Heyligen, H., Janssens, J., Raus, J., and Vandevyver, C. (1997) Mono-and bispecific single-chain antibody fragments for cancer therapy. Euro. J. Can. Prev. 5, 507–511.Google Scholar
  24. 24.
    Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., and Eggermont, A. A. (1995) Regression of advanced ovarian carcinoma by intraperi-toneal treatment with autologous T lymphocytes retargeted by a bispecific antibody. J. Natl. Cancer Inst. 87, 1463–1469.CrossRefPubMedGoogle Scholar
  25. 25.
    Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., Mrozek-Orlowski, M., et al. (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that over-expresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13, 2281–2292.PubMedGoogle Scholar
  26. 26.
    Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmyr, R., et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343, 1177–1183.CrossRefPubMedGoogle Scholar
  27. 27.
    Jerne, N. K. (1974) Towards a network theory of the immune system. Ann. Immunol. C 25, 373–389.Google Scholar
  28. 28.
    Mittleman, A., Chen, Z. J., Kageshita, T., Yang, H., Yamada, M., Baskind, P., Goldberg, N., Ahmed, T., and Arlin, Z. (1990) Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J. Clin. Invest. 86, 2136–2144.CrossRefGoogle Scholar
  29. 29.
    Mittelman, A., Wang, X., Matsumoto, K., and Ferrone, S. (1995) Antiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14, 175–181.CrossRefPubMedGoogle Scholar
  30. 30.
    Frodin, J. E., Faxas, M. E., Hagstrom, B., Lefvert, A. K., Masucci, G., Nilsson, B., Steinitz, M., Unger, P., and Mellstedt, H. (1991) Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome-an important antitumoral effector function? Hybridoma 4, 421–431.CrossRefGoogle Scholar
  31. 31.
    Madiyalakan, R., Sykes, T. R., Dharampaul, S., Sykes, C. J., Baum, R. P., Hor, G., and Noujaim, A. A. (1995) Antiidiotypic induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 14, 199–203.CrossRefPubMedGoogle Scholar
  32. 32.
    Durrant, L. G., Buckley, T. J., Denton, G. W., Hardcastle, J. D., Sewell, H. F., and Robins, R. A. (1994) Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res. 54, 4837–4840.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Ian T. W. Matthews
    • 1
  1. 1.ChemOvation Ltd.HorshamUK

Personalised recommendations